SEP 30·SEC EDGARLow
Frankel Stanley purchased $6K of DTIL
Frankel Stanley purchased 1,000 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.00 on 2026-09-28.
StockNASDAQ · US · USDHealthcare · Biotechnology
$DTIL
PRECISION BIOSCIENCES INC
Price · $DTILvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- $30K 3 txs
- Sells
- — 0 txs
Germano Geno J1× · $16K
10b5-1 share of filings0%
Top stories · $DTILMore →
SEP 30·investing.com
Tuesday’s insider buys and sells: Zedge, Corebridge and StoneX
Key insider trades reported: Howard Jonas bought 2.2M Zedge shares; Nippon Life bought 178K Corebridge shares; Philip Smith sold 56K StoneX shares; J W Jr Marriott and David S. Marriott each sold 3.5K Marriott shares; Jayshree Ullal sold 62K Arista shares. Transactions occurred in late September 2026, with varying share prices and volumes.
SEP 29·SEC EDGAR
Brown Melinda purchased $7K of DTIL
Brown Melinda purchased 1,135 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.27 on 2026-09-25.
DTIL sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DTIL (PRECISION BIOSCIENCES INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DTIL coverage spans insider activity, technology and earnings.
In the last 30 days, DTIL insiders filed 3 SEC Form 4 transactions — 3 purchases ($30K) and no sales. The most active reporter was Germano Geno J with 1 filing.
What's driving DTIL
Small insider purchase likely has minimal market impact.
Small insider buy may be viewed as a vote of confidence.
Small insider purchase may signal modest confidence but size is too low to move price.
Small insider purchase signals modest confidence but unlikely to move the stock materially.
The dosing marks a key milestone that could de‑risk the program and attract investor interest, but clinical outcomes remain uncertain.
AlphAI scores every news story that mentions DTIL with an AI model for sentiment and relevance, and aggregates insider trades from PRECISION BIOSCIENCES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $DTIL
Score
Frankel Stanley purchased $6K of DTIL
Frankel Stanley purchased 1,000 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.00 on 2026-09-28.
1 min readTuesday’s insider buys and sells: Zedge, Corebridge and StoneX
Key insider trades reported: Howard Jonas bought 2.2M Zedge shares; Nippon Life bought 178K Corebridge shares; Philip Smith sold 56K StoneX shares; J W Jr Marriott and David S. Marriott each sold 3.5K Marriott shares; Jayshree Ullal sold 62K Arista shares. Transactions occurred in late September 2026, with varying share prices and volumes.
2 min readBrown Melinda purchased $7K of DTIL
Brown Melinda purchased 1,135 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.27 on 2026-09-25.
1 min readGermano Geno J purchased $16K of DTIL
Germano Geno J purchased 2,609 shares of PRECISION BIOSCIENCES INC (DTIL) at $6.28 on 2026-09-25.
1 min readPrecision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences (DTIL) dosed the first patient in its Phase 1/2 FUNCTION-DMD trial for Duchenne muscular dystrophy (DMD). The trial evaluates PBGENE-DMD, a gene-editing therapy designed to restore near full-length dystrophin. Initial safety data is expected by year-end 2026. The study is enrolling patients aged 2-7 with specific DMD mutations.
2 min readPrecision BioSciences Posts Q2 Loss; PBGENE-HBV Delivers Clinical CccDNA Elimination Data
Precision BioSciences (DTIL) reported a Q2 2026 net loss of $32.7M, an increase from the prior year. The company presented clinical data for PBGENE-HBV, showing cccDNA elimination in hepatitis B patients. PBGENE-DMD, for Duchenne muscular dystrophy, is advancing with initial safety data expected by year-end. Cash reserves total $112.4M, supporting operations through 2028.
3 min readiECURE, Inc.: iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium
iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.
2 min readPrecision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% rem
6 min readPRECISION BIOSCIENCES INC (DTIL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. dtil-20260723 0001357874 FALSE 0001357874 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua
3 min readPRECISION BIOSCIENCES INC (DTIL): Entry into a Material Definitive Agreement
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. dtil-20260610 0001357874 FALSE 0001357874 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua
2 min readRelated tickers
More in Biotechnology- $SYRESpyre Therapeutics, Inc.
- $KURAKura Oncology, Inc.
- $ELVNEnliven Therapeutics, Inc.
- $ZLDPFZealand Pharma A/S/ADR
- $REGNREGENERON PHARMACEUTICALS, INC.
- $BRVEBraveheart Bio, Inc.
- $SLSSELLAS Life Sciences Group, Inc.
- $CLGNCollPlant Biotechnologies Ltd
- $CRVSCorvus Pharmaceuticals, Inc.
- $TLXTelix Pharmaceuticals Ltd